Drug related adverse event assessment in neonates in clinical trials and clinical care
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2390927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Nadir Yalcin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye. Hauptthemen laut MEDLINE: Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions, Severity of Illness Index. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Assessment of drug-related adverse events is essential to fully understand the benefit-risk balance of any drug exposure, weighing efficacy versus safety. This is needed for both drug labeling and clinical decision-making. Assessment is based on seriousness, severity and causality, be it more difficult to apply in neonates. Adverse event detection or prevention in the neonatal clinical setting is also more complicated because of polypharmacy, and off-label or unlicensed pharmacotherapy. AREAS COVERED: Tools became available to assess severity and causality of adverse events in neonates recruited in clinical trials. The first version of the Neonatal Adverse Event severity score (NAESS) reduced the inter-observer variability. Causality tools like the Naranjo score were also tailored to neonates. These tools are also instrumental to support proactive pharmacovigilance in clinical care, while multidisciplinary care teams and computerized pharmacovigilance using advanced data analysis, like machine learning are emerging approaches to develop effective decision strategies. EXPERT OPINION: All stakeholders involved in development of medicines or its clinical use should be aware of the limitations of the currently available assessment tools. Extension and optimization of these tools, advanced data analysis approaches, and capturing the variability in time-dependent physiology are warranted to improve pharmacovigilance in neonates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye.
- Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
- Department of Pediatrics, Division of Neonatology, McMaster University, Hamilton, ON, Canada.
- Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
- Department of Development and Regeneration, Leuven, Belgium.
- Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Nadir Yalcin, Karel Allegaert
Zitieren
APA
Yalcin, N., van den Anker, J., Samiee-Zafarghandy, S., & Allegaert, K. (2024). Drug related adverse event assessment in neonates in clinical trials and clinical care. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2390927
Vancouver
Yalcin N, van den Anker J, Samiee-Zafarghandy S, Allegaert K. Drug related adverse event assessment in neonates in clinical trials and clinical care. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2390927
BibTeX
@article{Yalcin2024,
author = {Yalcin, Nadir and van den Anker, John and Samiee-Zafarghandy, Samira and Allegaert, Karel},
title = {Drug related adverse event assessment in neonates in clinical trials and clinical care},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2390927}
}
EUVIMED